Fulvestrant

About

Therapy type: Hormone therapy

Therapy strategy: Estrogen receptor inhibition

Mappings

NCI Thesaurus: Fulvestrant (ncit:C1379)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
EMA (1) FDA (2)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant
EMA (1) FDA (2)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant
EMA (1) FDA (2)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant
FDA (1)	ER positive, HER2-negative, PIK3CA somatic variants	Invasive Breast Carcinoma	Alpelisib, Fulvestrant
FDA (1)	HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Alpelisib, Fulvestrant
FDA (1)	ER positive, HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Alpelisib, Fulvestrant
FDA (1)	ER positive, HER2-negative, PIK3CA somatic variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
FDA (1)	HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
FDA (1)	ER positive, HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
EMA (1) FDA (1)	AKT1 somatic variants, ER positive, HER2-negative	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
FDA (1)	AKT1 somatic variants, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
FDA (1)	AKT1 somatic variants, ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
EMA (1) FDA (1)	AKT1 amplification, ER positive, HER2-negative	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
FDA (1)	AKT1 amplification, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
FDA (1)	AKT1 amplification, ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
EMA (1) FDA (1)	ER positive, HER2-negative, PTEN nonsense variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
FDA (1)	HER2-negative, PR positive, PTEN nonsense variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
FDA (1)	ER positive, HER2-negative, PR positive, PTEN nonsense variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
EMA (1) FDA (1)	ER positive, HER2-negative, PTEN frameshift variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
FDA (1)	HER2-negative, PR positive, PTEN frameshift variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
FDA (1)	ER positive, HER2-negative, PR positive, PTEN frameshift variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
EMA (1) FDA (1)	ER positive, HER2-negative, PTEN splice site variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
FDA (1)	HER2-negative, PR positive, PTEN splice site variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
FDA (1)	ER positive, HER2-negative, PR positive, PTEN splice site variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
EMA (1) FDA (1)	ER positive, HER2-negative, PTEN deletion	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
FDA (1)	HER2-negative, PR positive, PTEN deletion	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
FDA (1)	ER positive, HER2-negative, PR positive, PTEN deletion	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
FDA (1)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant
FDA (1)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant
FDA (1)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant
EMA (1) FDA (1)	ER positive	Invasive Breast Carcinoma	Fulvestrant
FDA (1)	PR positive	Invasive Breast Carcinoma	Fulvestrant
FDA (1)	ER positive, PR positive	Invasive Breast Carcinoma	Fulvestrant
EMA (1) FDA (2) HSE (1)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Ribociclib
EMA (1) FDA (2) HSE (1)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib
EMA (1) FDA (2) HSE (1)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib
EMA (2) FDA (2) HSE (1)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Palbociclib
EMA (2) FDA (2) HSE (1)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib
EMA (2) FDA (2) HSE (1)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib
EMA (1) FDA (1)	ER positive, HER2-negative, PIK3CA somatic variants	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib
EMA (1) FDA (1)	HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib
EMA (1) FDA (1)	ER positive, HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib
EMA (1)	ER positive, HER2-negative, PIK3CA somatic variants	Invasive Breast Carcinoma	Alpelisib, Fulvestrant
EMA (1)	HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Alpelisib, Fulvestrant
EMA (1)	ER positive, HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Alpelisib, Fulvestrant
EMA (1)	ER positive, HER2-negative, PIK3CA somatic variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
EMA (1)	ER positive, HER2-negative, PIK3CA amplification	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
HSE (2)	ER negative	Invasive Breast Carcinoma	Fulvestrant